Integrated neuromodulation system for mood enhancement of a living human subject

Abstract

The present invention is an ingestable blended formulation which will cause a series of distinct biochemical changes in-vivo; initiate desirable psychological consequences in that person; and induce an observable increase in cognitive functions for that living human subject. In particular, the initiated psychological events will generate a positive change in one's personal perceptions, evoke optimism as the subjective state of mind, and elicit a more sociable attitude and favorable mood as the observable behavior of the affected human person. Moreover, in addition to the initiation of a more positive state of mind, another major result and effect of ingesting the blended formulation is an observable amplification of human brain functions and a substantive increase of human concentration, focus and memory.

What we claim is: 
     
       1. A non-prescription blended formulation suitable for ingestion by a living human subject, comprising: (a) two or more different naturally existing nootropic dopamine neurotransmitter agonists, (b) one or more naturally existing nootropic acetylcholine neurotransmitter agonists, (c) one or more naturally existing nootropic serotonin neurotransmitter agonists, (d) one or more naturally existing nootropic gamma-aminobutyric acid (GABA) neurotransmitter agonists, and (e) one or more nootropic adenosine antagonists, wherein the ratio of all individual nootropic neurotransmitter agonists to all individual nootropic adenosine antagonists is proportionally not less than 5:1, wherein the neurotransmitter replenishment balance for the admixture of essential active agents mathematically is zero (“0”) in value; and wherein there is a complete absence of any other kind of nootropic agonist or antagonist. 
     
     
       2. The blended formulation of  claim 1 , wherein each of said different nootropic neurotransmitter agonists is one selected from the group consisting of precursor compositions and synapse active molecules. 
     
     
       3. The blended formulation of  claim 2 , further comprising a biocompatible and non-toxic carrier medium selected from the group consisting of aqueous liquids and semi-solid hydrogels. 
     
     
       4. The blended formulation of  claim 1 , wherein each individual nootropic dopamine neurotransmitter agonist is selected from the group consisting of L-phenylalanine, L-tyrosine, N-acetyl-L-tyrosine, L-3,4-dihydroxyphenylalanine (L-DOPA), phenylethylamine, biopterin, amineptine, methylphenidate, selegiline, rasagiline, ropinirole, pramipexole, mucuna pruriens, modafinil, and citicoline. 
     
     
       5. The blended formulation of  claim 1 , wherein each individual nootropic acetylcholine neurotransmitter agonist is selected from the group consisting of choline, 2-dimethylaminoethanol (DMAE), meclofenoxate, alpha-glycerylphosphorylcholine (alpha-GPC), acetylcarnitine, pantothenic acid (Vitamin B 5 ), galantamine, huperzine A, donepezil, ispronicline, nicotine, and arecoline. 
     
     
       6. The blended formulation of  claim 1 , wherein each nootropic serotonin neurotransmitter agonist is selected from the group consisting of 5-hydroxytryptophan (or 5-HTP, 5-hydroxy-L-tryptophan), pyridoxal phosphate, pyridoxal-5′-phosphate, mesembrine, resveratrol, curcumin, piperine, harmal, rhodiola rosea, and tianeptine. 
     
     
       7. The blended formulation of  claim 1 , wherein each individual nootropic GABA neurotransmitter agonist is selected from the group consisting of ethanol, picrotoxin, and L-theanine. 
     
     
       8. The blended formulation of  claim 1 , wherein each individual nootropic adenosine receptor antagonist is selected from the group consisting of caffeine, theophylline, apaxanthine, theobromide, 8-cyclopentyl-1,3-dimethylxanthine (or CPX, 8-cyclopentyltheophylline), 8-cyclopentyl-1,3-dipropylxanthine (or DPCPX), 8-phenyl-1,3-dipropylxanthine, bamifylline, and rolofylline. 
     
     
       9. A fluid, non-prescription, blended formulation suitable for oral ingestion by a living human subject, comprising: (i) at least two and not more than six different naturally existing nootropic dopamine neurotransmitter agonists, (ii) at least one and not more than four different naturally existing nootropic acetylcholine neurotransmitter agonists, (iii) at least one and not more than three different naturally existing nootropic serotonin neurotransmitter agonists, (iv) at least one and not more than three different naturally existing nootropic GABA neurotransmitter agonists, (v) at least one and not more than three different naturally existing nootropic adenosine antagonists, and a biocompatible and non-toxic liquid carrier medium, wherein the ratio of all individual nootropic neurotransmitter agonists to all individual nootropic adenosine antagonists is proportionally not less than 5:1 and not more than 16:3, wherein the neurotransmitter replenishment balance for the admixture of essential active agents mathematically is zero (“0”) in value, and wherein there is a complete absence of any other kind of nootropic agonist or antagonist. 
     
     
       10. The blended formulation of  claim 9 , wherein each of said different nootropic neurotransmitter agonists is one selected from the group consisting of precursor compositions and synapse active molecules. 
     
     
       11. The blended formulation of  claim 10 , wherein said biocompatible and non-toxic carrier medium is one selected from the group consisting of aqueous liquids and semi-solid hydrogels. 
     
     
       12. The blended formulation of  claim 9 , wherein each individual nootropic dopamine neurotransmitter agonist is selected from the group consisting of L-phenylalanine, L-tyrosine, N-acetyl-L-tyrosine, L-DOPA, phenylethylamine, biopterin, amineptine, methylphenidate, selegiline, rasagiline, ropinirole, pramipexole, mucuna pruriens, modafinil, and citicoline. 
     
     
       13. The blended formulation of  claim 9 , wherein each individual nootropic acetylcholine neurotransmitter agonist is selected from the group consisting of choline, DMAE, meclofenoxate, alpha-GPC, acetylcarnitine, Vitamin B 5 , galantamine, huperzine A, donepezil, ispronicline, nicotine, and arecoline. 
     
     
       14. The blended formulation of  claim 9 , wherein each individual nootropic serotonin neurotransmitter agonist is selected from the group consisting of 5-hydroxytryptophan (or 5-HTP, 5-hydroxy-L-tryptophan), pyridoxal phosphate, pyridoxal-5′-phosphate, mesembrine, resveratrol, curcumin, piperine, harmal, rhodiola rosea, and tianeptine. 
     
     
       15. The blended formulation of  claim 9 , wherein each individual nootropic gamma-aminobutyric acid neurotransmitter agonist is selected from the group consisting of ethanol, picrotoxin, and L-theanine. 
     
     
       16. The blended formulation of  claim 9 , wherein each individual nootropic adenosine receptor antagonist is selected from the group consisting of caffeine, theophylline, apaxanthine, theobromide, 8-cyclopentyl-1,3-dimethylxanthine (or CPX, 8-cyclopentyltheophylline), 8-cyclopentyl-1,3-dipropylxanthine (or DPCPX), 8-phenyl-1,3-dipropylxanthine, bamifylline, and rolofylline.